NME8: The Potential Drug Target and Biomarker (G51314)

Target Name: NME8

NCBI ID: G51314

NME8

NME8: The Potential Drug Target and Biomarker

NME8 (N-Methyl-L-伪-Acetyltransferase 8) is a gene that encodes a protein located in the nucleus of the human chromosome. The function of this protein is not yet fully understood, but its potential involvement in various diseases has led to its potential as a drug target and biomarker. In this article, we will explore the potential drug target and biomarker of NME8 and its potential impact on human health.

Potential Drug Target

NME8 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are crucial for the development and progression of various diseases. One of the key functions of NME8 is its role in the regulation of DNA replication, which is critical for the development and progression of cancer.

NME8 has been shown to play a role in the regulation of the DNA replication process in various cancer types, including breast, ovarian, and prostate cancers. Studies have shown that inhibition of NME8 has led to a reduction in the growth and spread of these cancer types.

In addition to its role in cancer development, NME8 has also been shown to play a key role in the regulation of normal cellular processes. Studies have shown that NME8 is involved in the regulation of cell division, cell signaling, and cell adhesion.

Potential Biomarker

NME8 has also been identified as a potential biomarker for various diseases, including cancer. The detection and expression of NME8 have been shown to be affected by various diseases, including cancer, which suggests that NME8 may be a useful biomarker for the diagnosis and treatment of these diseases.

Studies have shown that NME8 is downregulated in various cancer types, including breast, ovarian, and prostate cancers. This downregulation has been associated with increased cancer cell proliferation and a reduced response to chemotherapy.

In addition, NME8 has also been shown to be involved in the regulation of the immune response, which is crucial for the development and progression of cancer. Studies have shown that NME8 plays a role in the regulation of the T-cell response, which is critical for the development and progression of cancer.

Conclusion

In conclusion, NME8 is a gene that has the potential to be a drug target and biomarker for various diseases. The regulation of DNA replication and cell division, as well as its involvement in the regulation of cell signaling and adhesion, make NME8 a promising target for the development of new cancer therapies.

Furthermore, the downregulation of NME8 has been shown to be involved in the regulation of various diseases, including cancer and the immune response. This suggests that NME8 may be a useful biomarker for the diagnosis and treatment of these diseases.

Overall, the potential drug target and biomarker of NME8 makes it an important area of research for the development of new treatments for various diseases. Further studies are needed to fully understand the role of NME8 in these diseases and its potential as a drug target and biomarker.

Protein Name: NME/NM23 Family Member 8

Functions: Probably required during the final stages of sperm tail maturation in the testis and/or epididymis, where extensive disulfide bonding of fibrous sheath (FS) proteins occurs. May be involved in the reduction of disulfide bonds within the sperm FS components. In vitro, it has neither NDP kinase nor reducing activity on disulfide bonds

The "NME8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NME8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets